CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: In vitro drug sensitivity and outcome

References

• Athale U H, Razzouk B I, Raimondi S C, Tong X, Behm F G, Head D R, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001; 97: 3727–3732
   PubMed Web of Science ®Google Scholar
• Pagano L, Pulsoni A, Vignetti M, et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia 2002; 16: 1622–1626
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Abella E, Krischer J P, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210–2214
   PubMed Web of Science ®Google Scholar
• Gamis A S, Woods W G, Alonzo T A, Buxton A, Lange B, Barnard D R, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol 2003; 21: 3415–3422
   PubMed Web of Science ®Google Scholar
• Ravindranath Y. Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 2003; 21: 3385–3387
   PubMed Web of Science ®Google Scholar
• Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 2000; 14: 786–791
   PubMed Web of Science ®Google Scholar
• Taub J W, Matherly L H, Stout M L, Buck S A, Gurney J G, Ravindranath Y. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996; 87: 3395–3403
   PubMed Web of Science ®Google Scholar
• Taub J W, Huang X, Matherly L H, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999; 94: 1393–1400
   PubMed Web of Science ®Google Scholar
• Taub J W, Stout M L, Buck S A, et al. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 1997; 11: 1594–1595
   PubMed Web of Science ®Google Scholar
• Zwaan C M, Kaspers G J, Pieters R, Hahlen K, Janka-Schaub G E, Zantwijk C H, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002; 99: 245–251
   PubMed Web of Science ®Google Scholar
• Savasan S, Buck S, Ravindranath Y. CD36 expression is associated with superior in vitro Ara-C sensitivity in acute megakaryoblastic leukemia with and without Down syndrome. Med Pediatr Oncol 2003; 41: 274–275, (O-070)
   Google Scholar
• Willman C L, Stewart C C. General principles of multiparameter flow cytometric analysis: applications of flow cytometry in the diagnostic pathology laboratory. Semin Diagn Pathol 1989; 6: 3–12
   PubMed Web of Science ®Google Scholar
• Terstappen L W, Johnson D, Mickaels R A, Chen J, Olds G, Hawkins J T, et al. Multidimensional flow cytometric blood cell differentiation without erythrocyte lysis. Blood Cells 1991; 17: 585–602
   PubMedGoogle Scholar
• Savasan S, Buck S, Ozdemir O, Hamre M I, Asselin B, Pullen J, Ravindranath Y. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia. Leuk Lymphoma 2005; 46: 833–841
   PubMed Web of Science ®Google Scholar
• Karandikar N J, Aquino D B, McKenna R W, Kroft S H. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. Am J Clin Pathol 2001; 116: 204–210
   PubMed Web of Science ®Google Scholar
• Carroll A, Civin C, Schneider N, Dahl N, Pappo A, Bowman P, et al. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 1991; 78: 748–752
   PubMed Web of Science ®Google Scholar
• Solary E, Casasnovas R O, Campos L, Bene M C, Faure G, Maingon P, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR−phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992; 6: 393–399
   PubMed Web of Science ®Google Scholar
• Mouthon M A, Freund M, Titeux M, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. Blood 1994; 84: 1085–1097
   PubMed Web of Science ®Google Scholar
• Tomer A, Harker L A. Measurements of in vivo megakaryocytopoiesis: studies in nonhuman primates and patients. Stem Cells 1996; 14(Suppl 1)18–30
   PubMedGoogle Scholar
• Dastugue N, Lafage-Pochitaloff M, Pages M P, Radford I, Bastard C, Talmant P, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2002; 100: 618–626
   PubMed Web of Science ®Google Scholar
• Minelli A, Morerio C, Maserati E, Olivier C, Panarello C, Bonvin L, et al. Meiotic origin of trisomy in neoplasms: evidence in a case of erythroleukaemia. Leukemia 2001; 15: 971–975
   PubMed Web of Science ®Google Scholar
• Wechsler J, Greene M, McDevitt M A, Anastasi J, Karp J E, Le Beau M M, Crispino J D. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148–152
   PubMed Web of Science ®Google Scholar
• Gurbuxani S, Vyas P, Crispino J D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004; 103: 399–406
   PubMed Web of Science ®Google Scholar
• Crispino J D. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 2005; 44: 40–44
   PubMed Web of Science ®Google Scholar
• Sandoval C, Pine S R, Guo Q, Sastry S, Stewart J, Kronn D, Jayabose S. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer 2005; 44: 85–91
   PubMed Web of Science ®Google Scholar
• Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood 2004; 103: 3242–3243
   PubMed Web of Science ®Google Scholar
• Elagib K E, Racke F K, Mogass M, Khetawat R, Delehanty L L, Goldfarb A N. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 2003; 101: 4333–4341
   PubMed Web of Science ®Google Scholar
• Shimamoto T, Ohyashiki K, Ohyashiki J H, Kawakubo K, Fujimura T, Iwama H, et al. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 1995; 86: 3173–3180
   PubMed Web of Science ®Google Scholar
• Bourquin J P, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci (USA) 2006; 103: 3339–3344
   PubMed Web of Science ®Google Scholar
• Febbraio M, Hajjar D P, Silverstein R L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785–791
   PubMed Web of Science ®Google Scholar
• Hu Z B, Yang G S, Li M, Miyamoto N, Minden M D, McCulloch E A. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Leukemia 1995; 9: 789–798
   PubMed Web of Science ®Google Scholar
• Padma M, Das U N. Effect of cis-unsaturated fatty acids on cellular oxidant stress in macrophage tumor (AK-5) cells in vitro. Cancer Lett 1996; 109: 63–75
   PubMed Web of Science ®Google Scholar
• Capizzi R L, White J C, Powell B L, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991; 28: 54–69
   PubMed Web of Science ®Google Scholar
• Yang M, Li K, Ng M H, Yuen P M, Fok T F, Li C K, et al. Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36. Thromb Res 2003; 109: 47–54
   PubMed Web of Science ®Google Scholar